Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Profit After Tax: 2015-2024

Historic Profit After Tax for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to -$125.8 million.

  • Seres Therapeutics' Profit After Tax fell 90.76% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 128.47%. This contributed to the annual value of -$125.8 million for FY2024, which is 33.85% up from last year.
  • Per Seres Therapeutics' latest filing, its Profit After Tax stood at -$125.8 million for FY2024, which was up 33.85% from -$190.1 million recorded in FY2023.
  • Seres Therapeutics' Profit After Tax's 5-year high stood at -$65.6 million during FY2021, with a 5-year trough of -$250.2 million in FY2022.
  • Over the past 3 years, Seres Therapeutics' median Profit After Tax value was -$190.1 million (recorded in 2023), while the average stood at -$188.7 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 281.46% in 2022, then spiked by 33.85% in 2024.
  • Seres Therapeutics' Profit After Tax (Yearly) stood at -$89.1 million in 2020, then climbed by 26.42% to -$65.6 million in 2021, then crashed by 281.46% to -$250.2 million in 2022, then rose by 24.00% to -$190.1 million in 2023, then surged by 33.85% to -$125.8 million in 2024.